| Dorothy Lynn Ferrelli, ANP-BC | |
|
100 Buckwalter Place Blvd Ste 130, Bluffton, SC 29910-5023 | |
| (843) 836-7100 | |
| (843) 836-7112 |
| Full Name | Dorothy Lynn Ferrelli |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 14 Years |
| Location | 100 Buckwalter Place Blvd Ste 130, Bluffton, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356642805 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2200X | Nurse Practitioner - Adult Health | 2010008180 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Candler Hospital | Savannah, GA | Hospital |
| Hilton Head Regional Medical Center | Hilton head island, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cora South Carolina Llc | 3173766334 | 126 |
| South Carolina Cancer Specialists | 9032007760 | 7 |
News Archive
Dyadic International, Inc., a leading biotechnology company focused on the development and manufacture of bioproducts based on its cutting-edge C1 technology to address the needs of multi-billion dollar markets for biofuels, biotherapeutics and industrial enzymes, announced today that it has signed a non-binding term sheet with EnGen Bio, Inc. for a potential outlicense, on an exclusive worldwide basis, of Dyadic's C1 platform technology for applications in biopharmaceutical drug development.
When medical marijuana is taken for chronic nerve pain, it may provide pain relief by reducing connections between the areas of the brain that process emotions and sensory signals, according to a study published in the September 5, 2018, online issue of Neurology, the medical journal of the American Academy of Neurology.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Over the past decades, the idea that all adults should get regularly screened for cancer - with mammograms, colonoscopies and prostate specific antigen blood tests - has been conveyed to the public time after time.
› Verified 7 days ago
| Entity Name | South Carolina Cancer Specialists |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912177239 PECOS PAC ID: 9032007760 Enrollment ID: O20040305000281 |
News Archive
Dyadic International, Inc., a leading biotechnology company focused on the development and manufacture of bioproducts based on its cutting-edge C1 technology to address the needs of multi-billion dollar markets for biofuels, biotherapeutics and industrial enzymes, announced today that it has signed a non-binding term sheet with EnGen Bio, Inc. for a potential outlicense, on an exclusive worldwide basis, of Dyadic's C1 platform technology for applications in biopharmaceutical drug development.
When medical marijuana is taken for chronic nerve pain, it may provide pain relief by reducing connections between the areas of the brain that process emotions and sensory signals, according to a study published in the September 5, 2018, online issue of Neurology, the medical journal of the American Academy of Neurology.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Over the past decades, the idea that all adults should get regularly screened for cancer - with mammograms, colonoscopies and prostate specific antigen blood tests - has been conveyed to the public time after time.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dorothy Lynn Ferrelli, ANP-BC 45 Hospital Center Cmns, Hilton Head Island, SC 29926-2837 Ph: (843) 689-2895 | Dorothy Lynn Ferrelli, ANP-BC 100 Buckwalter Place Blvd Ste 130, Bluffton, SC 29910-5023 Ph: (843) 836-7100 |
News Archive
Dyadic International, Inc., a leading biotechnology company focused on the development and manufacture of bioproducts based on its cutting-edge C1 technology to address the needs of multi-billion dollar markets for biofuels, biotherapeutics and industrial enzymes, announced today that it has signed a non-binding term sheet with EnGen Bio, Inc. for a potential outlicense, on an exclusive worldwide basis, of Dyadic's C1 platform technology for applications in biopharmaceutical drug development.
When medical marijuana is taken for chronic nerve pain, it may provide pain relief by reducing connections between the areas of the brain that process emotions and sensory signals, according to a study published in the September 5, 2018, online issue of Neurology, the medical journal of the American Academy of Neurology.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Over the past decades, the idea that all adults should get regularly screened for cancer - with mammograms, colonoscopies and prostate specific antigen blood tests - has been conveyed to the public time after time.
› Verified 7 days ago
Jennifer Dykes Price, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1006 Fording Island Rd, Bluffton, SC 29910 Phone: 866-389-2727 | |
Mrs. Jennifer Jacquelyn Green, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 25 Sherington Dr, Suite D, Bluffton, SC 29910 Phone: 843-757-5559 Fax: 843-757-5546 | |
Mrs. Denise Raney Raney, NP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 132 Bluffton Rd, Bluffton, SC 29910 Phone: 843-706-7090 Fax: 843-706-7078 | |
Mrs. Mary Ellen Groff, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 40 Okatie Ctr Blvd Ste 100, Bluffton, SC 29909 Phone: 843-708-8888 Fax: 843-705-7024 | |
Mrs. Suzanne W Deckelbaum, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 350 Fording Island Rd Ste 100, Bluffton, SC 29910 Phone: 843-837-4400 Fax: 843-837-4440 | |
Mrs. Anne Marie Willmann, APN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 11 Parklands Dr Unit 2218, Bluffton, SC 29910 Phone: 859-992-5121 | |
Mrs. Gail Elizabeth Kane, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3 Progressive St, Bluffton, SC 29910 Phone: 843-548-0533 Fax: 843-815-9121 |